tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

OKUR Stock Latest News

OnKure Therapeutics Advances Cancer Drug Development
Company AnnouncementsOnKure Therapeutics Advances Cancer Drug Development
23h ago
OKUR
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
PremiumThe Fly
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
1d ago
OKUR
OnKure Therapeutics’ Strategic Delay and Confidence in PI3Ka Inhibitor Development Supports Buy Rating
PremiumRatings
OnKure Therapeutics’ Strategic Delay and Confidence in PI3Ka Inhibitor Development Supports Buy Rating
2M ago
OKUR
OnKure Therapeutics Updates on PI3Kα Inhibitor Progress
PremiumCompany Announcements
OnKure Therapeutics Updates on PI3Kα Inhibitor Progress
2M ago
8K
OKUR
Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position
PremiumRatings
Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position
2M ago
OKUR
OnKure Elects Directors at Annual Stockholder Meeting
PremiumCompany AnnouncementsOnKure Elects Directors at Annual Stockholder Meeting
3M ago
8K
OKUR
One new option listing and nine option delistings on May 19th
Premium
The Fly
One new option listing and nine option delistings on May 19th
3M ago
J
DFS
Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics
Premium
Ratings
Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics
3M ago
OKUR
OnKure Therapeutics Reports Q1 2025 Progress and Financials
PremiumCompany Announcements
OnKure Therapeutics Reports Q1 2025 Progress and Financials
3M ago
OKUR
OnKure Therapeutics reports Q1 EPS ($1.19), consensus ($1.38)
PremiumThe Fly
OnKure Therapeutics reports Q1 EPS ($1.19), consensus ($1.38)
3M ago
OKUR
OnKure Therapeutics sees cash runway into 4Q26
PremiumThe Fly
OnKure Therapeutics sees cash runway into 4Q26
3M ago
OKUR
OnKure Therapeutics initiated with an Outperform at Evercore ISI
PremiumThe Fly
OnKure Therapeutics initiated with an Outperform at Evercore ISI
4M ago
OKUR
OnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright
PremiumThe FlyOnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright
5M ago
OKUR
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
Premium
Ratings
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
5M ago
OKUR
Oppenheimer biotech analyst holds an analyst/industry conference call
Premium
The Fly
Oppenheimer biotech analyst holds an analyst/industry conference call
5M ago
AZN
LLY
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
PremiumRatings
Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects
5M ago
OKUR
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
PremiumCompany Announcements
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
5M ago
OKUR
OnKure Therapeutics Reports Progress and Financials
PremiumCompany Announcements
OnKure Therapeutics Reports Progress and Financials
5M ago
OKUR
OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer
PremiumThe Fly
OnKure Therapeutics price target lowered to $30 from $35 at Oppenheimer
5M ago
OKUR
OnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)
PremiumThe FlyOnKure Therapeutics reports Q4 EPS ($1.37), consensus (86c)
5M ago
OKUR
OnKure Therapeutics initiated with a Buy at JonesResearch
Premium
The Fly
OnKure Therapeutics initiated with a Buy at JonesResearch
7M ago
LLY
OKUR
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Premium
The Fly
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
8M ago
LLY
ARVN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >